Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Impairment expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zomedica

Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. It offers products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Its TRUFORMA biosensor platform is designed to assist practitioners in the diagnosis of complex conditions. The company was founded by Gerald L. Solensky. on January 7, 2013 and is headquartered in Ann Arbor, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zomedica reports revenue growth and product advancements amidst profitability challenges

Zomedica's 2022 performance reflects revenue growth and product advancements, though challenges in profitability persist. The company's strategic focus on companion animal healthcare presents growth opportunities through innovation and market stability. Addressing expense management, stock stability, and leveraging market trends will be key for Zomedica's future success.

Zomedica reports robust Q1 earnings, eyes global equine market

Zomedica's Q1 2023 showcased strong revenue growth, particularly driven by TRUFORMA and international sales.
The company's focus on maintaining margins, expanding marketing efforts, and targeting global equine markets positions it for future success.
Challenges include the closure of the cancer assay program and operational hurdles in achieving the 70% gross margin target.
Opportunities lie in the launch of new assays, international expansion, and investor engagement beyond quarterly updates.

Zomedica reports robust Q2 earnings, eyes international expansion and product launches

Zomedica's Q2 performance reflects strong revenue growth and strategic investments for future profitability.
Despite challenges like increased OpEx and lower margins, the company is focused on long-term growth through product launches and market expansion.
Opportunities lie in international market exploration, upcoming product launches, and investor engagement strategies.

Zomedica reports record revenues, eyes global expansion amidst stock challenges

Zomedica's Q3 performance reflects strong revenue growth and strategic acquisitions, despite facing challenges like potential delisting and net losses.
The company's focus on new product launches, international expansion, and partnerships presents opportunities for future growth and market diversification.
Overall, Zomedica aims to drive towards cash flow breakeven by leveraging innovative products and maintaining a strong liquidity position.

Zomedica reports record revenues, eyes profitability through strategic growth

Zomedica's strong financial performance in Q4 2023 and full-year results, coupled with a robust cash position and strategic growth initiatives, position the company for future success.
While facing challenges related to compliance requirements and integration costs, Zomedica's focus on innovation, market expansion, and profitability goals present opportunities for sustained growth.
By balancing operational efficiency, product development, and financial discipline, Zomedica aims to drive revenue growth, enhance market presence, and deliver long-term value to shareholders.

Zomedica reports revenue growth and strong cash position in Q1

Zomedica's Q1 2024 performance showed revenue growth driven by key segments, strong cash position, and focus on operational efficiency. The company faces challenges in managing expenses and achieving aggressive revenue targets. Opportunities lie in expanding product lines, international sales, and maintaining financial strength.

Zomedica reports Q2 revenue growth amidst challenges and opportunities

Zomedica's Q2 performance showed revenue growth but with challenges in sales force and noncash charges.
Strengths include achieving milestones and expanding facilities, while opportunities lie in international expansion.
The company faces the task of managing cash burn and finding a new CFO.
Expectations for the second half of 2024 include revenue growth and operational focus.

Zomedica reports record Q3 revenue, eyes global expansion opportunities

Zomedica's Q3 2024 performance showcased revenue growth, margin strength, and cost reduction efforts, positioning the company for future profitability. Strategic international partnerships and product innovations underscore growth potential.
While challenges in achieving profitability persist, Zomedica's focus on operational efficiency and global expansion presents opportunities for sustained growth. Addressing investor inquiries and executing on strategic initiatives will be key to unlocking future value.
With a solid cash position, ongoing product enhancements, and expansion into new markets, Zomedica is poised for growth. Clear communication on financial targets, operational milestones, and strategic direction will be crucial for investor confidence and market success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ANN ARBOR, MI / ACCESSWIRE / June 15, 2022 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for companion animals, today announced it has signed a definitive agreement to acquire substantially all of the assets of Revo Squared LLC ("Revo"). Revo's innovative MicroView digital cytology platform will provide veterinarians with best-in-class image quality while providing the first in-clinic automated slide preparation system.

Zomedica to Acquire Assets of Innovative Veterinary Imaging Company Revo Squared

ANN ARBOR, MI / ACCESSWIRE / June 13, 2022 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for companion animals, has initiated a study to evaluate shock wave therapy as a treatment for Exercised Induced Pulmonary Hemorrhage (EIPH). EIPH or "bleeding" occurs in horses when pulmonary blood vessels in the lungs rupture after intense exercise.

Zomedica to Investigate Shock Wave Therapy of Exercised Induced Pulmonary Hemorrhage in Horses

ANN ARBOR, MI / ACCESSWIRE / June 8, 2022 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, is pleased to announce today that Larry Heaton, Zomedica's Chief Executive Officer, will present at the JMP Securities Life Sciences Conference. Mr. Heaton will present a corporate overview and update on Zomedica.

Zomedica to Present at JMP Securities Life Sciences Conference

Didi Global

Grab Holdings Ltd

Which penny stocks are you watching right now? The post Top Penny Stocks to Buy in June 2022?

Top Penny Stocks to Buy in June 2022? 3 to Watch Right Now

ANN ARBOR, MI / ACCESSWIRE / June 2, 2022 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, announced that it has appointed Karen DeHaan-Fullerton as its General Counsel and Corporate Secretary. She joined the Zomedica team on May 31, 2022.

Karen DeHaan-Fullerton Joins Zomedica as General Counsel and Corporate Secretary

ANN ARBOR, MI / ACCESSWIRE / May 19, 2022 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for companion animals, today announced that it has purchased a $1.0 million convertible note from Structured Monitoring Products, Inc. (SMP), makers of the VetGuardianTM wireless remote pet monitoring platform, and in connection therewith has acquired the option to act as a sales agent for SMP's platform. Under the terms of the agreement, Zomedica will also have the option to acquire the VetGuardian product line for use in Animal Health.

Zomedica Enters Into Strategic Investment and Potential Collaboration for VetGuardian Monitoring Product Line

NEW YORK, NY / ACCESSWIRE / May 18, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid cap publicly traded companies recently issued a new C-Level interview featuring Larry Heaton, CEO of Zomedica Corp. Mark Roberts, Senior Editor at TradersNewsSource.com recently conducted the Interview with Larry Heaton, CEO of Zomedica Corp. (NYSE American:ZOM). Mark diligently focused on questions he thought would be on the minds of most current and future shareholders.

Traders News Source Interviews Larry Heaton, CEO of Zomedica Corp.

ANN ARBOR, MI / ACCESSWIRE / May 16, 2022 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, is pleased to announce the interview with Juan Costello, Senior Analyst with the Wall Street Analyzer, and Larry Heaton, Zomedica's Chief Executive Officer. You can visit The Wall Street Analyzer (https://wallstreetanalyzer.com/2022/05/13/zomedica-corp-nyse-americanzom/) to listen to the full interview.

Zomedica CEO Interview with Wall Street Analyzer Discusses First Quarter 2022 Earnings and Future Plans

Alzamend Neuro

Drive Shack

Which penny stocks are you watching right now? The post 3 Penny Stocks to Add to Your Watchlist This Coming Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks to Add to Your Watchlist This Coming Week

Zomedica Corp (NASDAQ: ZOM) shares are trading lower by 4.99% at $0.20. The company reported first-quarter earnings results during Tuesday's after-hours session.

Why Zomedica Shares Are Falling Today

ANN ARBOR, MI / ACCESSWIRE / May 10, 2022 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, reported consolidated financial results for the three months ended March 31, 2022. Amounts, unless specified otherwise, are expressed in U.S. dollars, and presented under accounting principles generally accepted in the United States of America ("U.S. GAAP").

Zomedica Announces First Quarter 2022 Revenues of $3.8 Million; 74% Gross Margin & $192.3 Million in Cash; Revenue up 38% from 2021 Combined Revenues

ANN ARBOR, MI / ACCESSWIRE / May 4, 2022 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for companion animals, today announced its sponsorship with the American Association of Feline Practitioners (AAFP). "The AAFP supports feline practitioners by providing tools, guidelines and resources to assist in delivering continuing, high-quality service to their cat patients" said Larry Heaton, Zomedica's Chief Executive Officer, "We are honored to partner with such an organization to provide a healthy future for the feline veterinary profession.

Zomedica(R) Supports Feline Animal Health With American Association of Feline Practitioners' Sponsorship

Tencent Music Entertainment Group 

Uranium Energy

Check these 3 penny stocks out for your May list The post Hot Penny Stocks For Traders to Watch in May 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks For Traders to Watch in May 2022

ANN ARBOR, MI / ACCESSWIRE / April 27, 2022 / Zomedica Corp. (NYSE American:ZOM), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, announced today that Larry Heaton, Chief Executive Officer, will provide a strategic update and discuss first quarter 2022 earnings at the upcoming H.C. Wainwright Global Investment Conference, scheduled for 11:30 am ET on May 24, 2022.

Zomedica to Present at H.C. Wainwright Global Investment Conference

ANN ARBOR, MI / ACCESSWIRE / April 13, 2022 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for companion animals, is pleased to announce that the PulseVet system has been named the Official Shock Wave Therapy of the American Quarter Horse Association (AQHA). Zomedica's PulseVet system is a world leader in electro-hydraulic shock wave technology for the treatment of a wide variety of conditions in veterinary patients.

Zomedica's Announces Designation of Pulsevet System as the Official Shock Wave Therapy of the American Quarter Horse Association

ANN ARBOR, MI / ACCESSWIRE / April 4, 2022 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for companion animals, today announced the commercial launch of its newest assay - endogenous ACTH (eACTH) - for the TRUFORMA In-Clinic Biosensor Testing Platform. Larry Heaton, Zomedica's Chief Executive Officer, commented, "The proprietary TRUFORMA eACTH assay will bring a valuable diagnostic tool for veterinarians into their clinic for the first time.

Zomedica Announces Launch of eACTH Assay for Truforma(R) Platform

Digital World Acquisition Corp

These stocks are full of risk and losses are likely to mount in the future.

2 Meme Stocks Investors Should Avoid at All Costs

Zomedica said last year that Truforma would revolutionize veterinary care with radio waves. Now it would rather talk about PulseVet, which it bought in October The post Dogs Win, Investors Lose With Zomedica appeared first on InvestorPlace.

Dogs Win, Investors Lose With Zomedica

ZOM stockholders are likely to grow increasingly frustrated with management's misplaced optimism and the lack of Truforma sales. The post It's Going to Take a Lot to Get Zomedica Stock Out of the Doghouse appeared first on InvestorPlace.

It's Going to Take a Lot to Get Zomedica Stock Out of the Doghouse

Southwestern Energy

Tellurian

Tips and tricks on making money with penny stocks in 2022 The post How to Make Money With Penny Stocks During Geopolitical Conflict  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Make Money With Penny Stocks During Geopolitical Conflict

Zomedica Corp. (NYSEAMERICAN:ZOM) finally has a catalyst that could be a game-changer. It has reported $4.1 million in revenue for full-year 2021.

Will the PulseVet Acquisition Continue to Deliver Sales for Zomedica?

ANN ARBOR, MI / ACCESSWIRE / March 1, 2022 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for companion animals, today reported consolidated financial results for the year ended December 31, 2021. Amounts, unless specified otherwise, are expressed in U.S. dollars and presented under accounting principles generally accepted in the United States of America ("U.S. GAAP").

Zomedica Corporation Reports 2021 Fourth Quarter & Full Year Results

There's some reason for cautious optimism.

Zomedica Stock Jumped Today. Is It a Buy?

Nordic American Tankers

NeuroSense Therapeutics Ltd

Add these penny stocks to your March 2022 watchlist The post Top Penny Stocks to Buy in March 2022, 3 For Your List  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks to Buy in March 2022, 3 For Your List

Investors liked the company's fourth-quarter revenue growth.

News for Zomedica Stock (ZOM)